The FDA sent a warning letter this month to Novo Nordisk, alleging the drugmaker failed to report, in a timely manner, potential side effects in patients who took its popular medications containing semiglutide.
FDA sends warning letter to maker of Ozempic, Wegovy over unreported potential GLP-1 side effects
Related Posts
-
FDA sends warning letter to maker of Ozempic, Wegovy over unreported potential GLP-1 side effects
The FDA sent a warning letter this month to Novo Nordisk, alleging the drugmaker failed…
-
Des Moines airport travelers brace for TSA delays as government shutdown continues
Travelers at Des Moines International Airport arrived early as the federal shutdown continues, though TSA…
-
Neal Smith Wildlife Refuge unveils plans for $7 million rebuild
The Neal Smith Wildlife Refuge in Prairie City is planning a $7 million rebuild of…
-
Conversations between State Center, Iowa DOT lead to safe upgrade for dangerous Hwy. 30 intersection
“Oftentimes, people just feel like their voices don’t matter, but this is a great example…
Leave a Reply